Bronchoconstriction-related targets

Bronchoconstriction-related targets refer to a collection of molecular entities that regulate the contraction and relaxation of airway smooth muscle (ASM). The most prominent targets include the beta-2 adrenergic receptor (ADRB2), which promotes bronchodilation via the Gs-cAMP-PKA pathway, and the muscarinic M3 receptor, which mediates bronchoconstriction through Gq-coupled phospholipase C activation (StatPearls, 2024; NIH, 2023). Other critical targets include the cysteinyl leukotriene receptor 1 (CysLT1), which responds to potent inflammatory bronchoconstrictors, and phosphodiesterase 4 (PDE4), an enzyme that degrades cAMP in ASM and inflammatory cells (PubMed, 2017; MDPI, 2024). These targets are central to the pathophysiology of obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Pharmacological management involves the use of agonists (e.g., beta-2 agonists) to induce muscle relaxation or antagonists (e.g., anticholinergics and leukotriene blockers) to prevent or reverse narrowing of the airways (StatPearls, 2024). Effective modulation of these targets is essential for maintaining airway patency and improving respiratory function in patients with bronchospastic conditions.

Other names

Airway smooth muscle contraction targetsBronchospasm targetsBronchodilator targetsTargets for obstructive lung diseaseBronchoconstrictor targets

Agonism of beta-2 adrenergic receptors, antagonism of muscarinic M3 receptors, antagonism of cysteinyl leukotriene receptor 1, and inhibition of phosphodiesterase 4.